Figure 2.
Anti-PD-1_CTLA-4 treatment resistance is eradicated by anti-Ly6C antibody treatment. (A-H) 129/Sv mice (n = 5) were treated weekly with indicated antibodies beginning on day 7 after a subcutaneous cancer cell injection (0.1 x 106 344SQ cells, 1 x 106 344P cells, 2 x 106 393P cells, or 1 x 106 412P cells per mouse). Dosage of all animal studies: 200 µg of anti-PD-1, 200 µg of anti-CTLA-4, 150 µg of anti-CD25, 300 µg of anti-Gr-1, 250 µg of anti-Ly6G, 200 µg of anti-Ly6C per mouse per injection. p values were calculated with t-test. n.s., no significant difference; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.